K-S TAN1,2,3, S MCDONALD4,5, WE HOY1,2
1NHMRC CKD.CRE and CKD.QLD, Brisbane, Australia, 2Faculty of Medicine, University of Queensland., Brisbane, Australia, 3Renal unit, Logan Hospital & Metro South Health Service, Brisbane, Australia, 4Central and Northern Adelaide Renal And Transplant Service, Adelaide, Australia, 5Adelaide Medical School, University of Adelaide, Adelaide, Australia

Background: Diabetes Mellitus (DM) is a common cause of end stage kidney failure (ESKF) and CKD in Australia. The CKD.QLD registry is a Queensland-based registry of patients with CKD who are followed up in the state’s public hospital renal units and have provided informed consent. Enrolment commenced in 2011.
Aims: Define baseline characteristics, mortality and renal outcomes of all Aboriginal and Torres Strait Islander (ATSI) patients with DM and CKD in the CKD.QLD registry.
Methods: ATSI patients with DM enrolled in the registry between 01/01/2011 and 31/12/2016 inclusive were included. Baseline characteristics, incidence of ESKF (defined as eGFR <10ml/min for >3 months or commencement of RRT) or death without ESKF were determined. Censor date was 31/12/2017.
Results: 270 patients (56% women) comprising 11.7% of all registry patients with DM identified as ATSI. Mean follow up was 2.96 years. Mean age at enrolment was 60.1y (SD 11.4). 53% were incident patients (enrolled within 6 months of first appointment).267 patients (99%) had DM2 (55% on insulin). Median eGFR at enrolment was 38ml/min (IQR 21-58) and 60% had enrolment eGFR <45ml/min. 66% had ACR>30mg/mmol (A3) at enrolment. At censor date, 79 patients had developed ESKF first (8 committed to supportive care) and 47 had died without ESKF, giving ESKF rate of 9 and death rate of 5.3 per 100 patient years f/u. 95% of ESKF patients had A3 at enrolment. All 69 patients who commenced RRT went onto dialysis (no pre-emptive transplants).
Conclusions: As befits a population attending specialist follow-up, patients had both significantly reduced eGFR and residual proteinuria at enrolment. The event rate was high.  Few patients with ESKD (10%) were managed conservatively.

Nephrologist and Clinical Pharmacologist.


The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

© 2015 - 2016 Conference Design Pty Ltd